ACON Key Statistics, Chart & Performance
The current stock price of ACON is 4.78 USD. In the past month the price decreased by -29.29%. In the past year, price decreased by -99.55%.
ACON Latest News, Press Relases and Analysis
ACON Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 31.02 | 39.47B | ||
| DOCS | DOXIMITY INC-CLASS A | 26.7 | 8.24B | ||
| WAY | WAYSTAR HOLDING CORP | 25.75 | 6.60B | ||
| HTFL | HEARTFLOW INC | N/A | 2.82B | ||
| CERT | CERTARA INC | 18.66 | 1.49B | ||
| SDGR | SCHRODINGER INC | N/A | 1.35B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.32B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 646.5 | 1.10B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.07B | ||
| PHR | PHREESIA INC | N/A | 1.03B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 8 | 950.40M | ||
| HSTM | HEALTHSTREAM INC | 32.5 | 655.71M |
Related stock screener links
About ACON
Company Profile
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Company Info
ACLARION INC
8181 Arista Place, Ste 100
Broomfield COLORADO US
Employees: 6
Phone: 18332752266
ACLARION INC / ACON FAQ
What does ACLARION INC do?
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
What is the stock price of ACLARION INC today?
The current stock price of ACON is 4.78 USD. The price decreased by -41.49% in the last trading session.
Does ACLARION INC pay dividends?
ACON does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACON stock?
ACON has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ACLARION INC (ACON) based on its PE ratio?
ACLARION INC (ACON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-801.7).
Is ACLARION INC (ACON) expected to grow?
The Revenue of ACLARION INC (ACON) is expected to grow by 40% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for ACON stock?
You can find the ownership structure of ACLARION INC (ACON) on the Ownership tab.
ACON Technical Analysis
ACON Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACON. ACON has a great financial health rating, but its profitability evaluates not so good.
ACON Financial Highlights
Over the last trailing twelve months ACON reported a non-GAAP Earnings per Share(EPS) of -801.7. The EPS increased by 93.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.97% | ||
| ROE | -59.1% | ||
| Debt/Equity | 0 |
ACON Forecast & Estimates
7 analysts have analysed ACON and the average price target is 23.46 USD. This implies a price increase of 390.79% is expected in the next year compared to the current price of 4.78.
For the next year, analysts expect an EPS growth of 99.79% and a revenue growth 40% for ACON